Mesoblast Limited (NASDAQ: MESO) and Cellular Dynamics International (NASDAQ:ICEL) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, valuation, analyst recommendations and institutional ownership.


This table compares Mesoblast Limited and Cellular Dynamics International’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Mesoblast Limited -3,184.70% -14.79% -11.55%
Cellular Dynamics International -88.12% -57.59% -38.09%

Earnings and Valuation

This table compares Mesoblast Limited and Cellular Dynamics International’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Mesoblast Limited $2.41 million 254.83 -$86.99 million ($0.96) -7.53
Cellular Dynamics International N/A N/A N/A N/A N/A

Cellular Dynamics International has higher revenue, but lower earnings than Mesoblast Limited.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Mesoblast Limited and Cellular Dynamics International, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mesoblast Limited 0 2 4 0 2.67
Cellular Dynamics International 0 0 0 0 N/A

Mesoblast Limited presently has a consensus target price of $14.25, indicating a potential upside of 97.10%. Given Mesoblast Limited’s higher possible upside, equities research analysts clearly believe Mesoblast Limited is more favorable than Cellular Dynamics International.

Institutional and Insider Ownership

3.0% of Mesoblast Limited shares are owned by institutional investors. 18.8% of Mesoblast Limited shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.


Mesoblast Limited beats Cellular Dynamics International on 7 of the 8 factors compared between the two stocks.

About Mesoblast Limited

Mesoblast Limited is engaged in developing cell-based medicines. The Company has leveraged its technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a portfolio of late-stage product candidates. Its allogeneic, off-the-shelf cell product candidates target advanced stages of diseases with high, unmet medical needs, including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions.

About Cellular Dynamics International

Cellular Dynamics International, Inc. develops and produces functioning human cells in industrial quantities. The Company’s products include true human cells in multiple cell types (iCell products), human induced pluripotent stem cells (iPSCs) and custom iPSCs and iCell products (MyCell products). It markets its products for use in life science in vitro research and development, as well as applied product testing, stem cell banking and in vivo cellular therapeutics. It is also in the process of developing human cells as cellular therapeutics. The market for in vitro drug discovery, toxicity testing and applied testing, including chemical safety, has employed models, such as primary cells, transformed (immortalized) cells and live animals that act as surrogates for functioning human cells. Its iCell and MyCell products consist of iCell Cardiomyocytes, iCell Neurons, iCell DopaNeurons, iCell Endothelial Cells, iCell Hepatocytes, MyCell and Media and reprogramming kit.

Receive News & Ratings for Mesoblast Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast Limited and related companies with's FREE daily email newsletter.